Fortress Biotech Announces Exclusive License Agreement With Fuji Yakuhin to Develop Dotinurad in North America and Europe

NEXT STORY
G1 Therapeutics Initiates Randomized Double Blind Placebo Controlled Phase 2 Study of COSELA™ (trilaciclib) in Non-Small Cell Lung Cancer (PRESERVE 4)
PREV STORY
Revenue Cycle Management Market Size 2021 | Is Expected to Reach USD 258.16 Billion, Registering a CAGR of 13.0%
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Crown Bioscience to Showcase Scientific Expertise in Preclinical Evaluation of Investigational Cancer Compounds at the American Association for Cancer Research’s International Conference on Molecular Targets and Cancer Therapeutics

SANTA CLARA, Calif., Oct. 17, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary ...

author_avatar
NASDAQ Market News

Oasmia Pharmaceutical AB (publ) Interim report for the period May 1 – July 31, 2019

author_avatar
NASDAQ Market News

Bavarian Nordic Announces Initiation of Phase 2 Trial Evaluating the Combination Therapy of CV301 and Atezolizumab in Bladder Cancer

Bavarian Nordic-sponsored study has commenced dosingStudy marks the second of three planned Phase 2 ...

author_avatar
NASDAQ Market News